Get started
Author

Mu‐Yang Huang

Observed names: Mu-Yang HUANG, Mu-Yang Huang, Muyang HUANG
Institution: University of Macau
OpenAlex ID: A5067488985
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
2020 · Mu-Yang Huang, Xiao-Ming Jiang, et al. · Pharmacology & Therapeutics · 134
Regulation of CD47 expression in cancer cells
2020 · Can-Yu Huang, Zi-Han Ye, et al. · Translational Oncology · 128
PDF
Anticancer drug discovery from Chinese medicinal herbs
2018 · Mu-Yang Huang, Le-Le Zhang, et al. · Chinese Medicine · 104
PDF
Bioactive platycodins from Platycodonis Radix: Phytochemistry, pharmacological activities, toxicology and pharmacokinetics
2020 · Le-Le Zhang, Mu-Yang Huang, et al. · Food Chemistry · 94
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
2017 · Xiao-Ming Jiang, Yu-Lian Xu, et al. · Acta Pharmacologica Sinica · 77
PDF
Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10
2023 · Mu-Yang Huang, Yu-Chi Chen, et al. · Pharmacological Research · 70
Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells
2019 · Mu-Yang Huang, Xiao-Ming Jiang, et al. · Food and Chemical Toxicology · 63
Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells
2022 · Yu-Chi Chen, Xin-Ling He, et al. · Biochemical Pharmacology · 50
Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells
2020 · Luo-Wei Yuan, Xiao-Ming Jiang, et al. · Phytomedicine · 49
Regulation of CD47 expression by interferon-gamma in cancer cells
2021 · Zi-Han Ye, Xiao-Ming Jiang, et al. · Translational Oncology · 45
PDF
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
2022 · Zi-Han Ye, Wei-Bang Yu, et al. · Acta Pharmaceutica Sinica B · 41
c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2
2021 · Min-Xia Su, Yu-Lian Xu, et al. · Acta Pharmaceutica Sinica B · 28
PDF
Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products
2024 · Le-Le Zhang, Du-Juan Zhang, et al. · Phytomedicine · 21
Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells
2018 · Le-Le Zhang, Xiao-Ming Jiang, et al. · Phytomedicine · 21
Glutathione peroxidase 8 expression on cancer cells and cancer‐associated fibroblasts facilitates lung cancer metastasis
2022 · Yu‐Lian Xu, Luo‐Wei Yuan, et al. · MedComm · 18
Cancer statistics and trends in China: the potential of natural product application
2024 · Ting LI, Muyang HUANG, et al. · Chinese Journal of Natural Medicines · 17
Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells
2020 · Yu-Chi CHEN, Mu-Yang HUANG, et al. · Chinese Journal of Natural Medicines · 17
Repurposing Cardiac Glycosides to Potentiate CD47 Blockade through Calreticulin‐mediated Phagocytic Effects for Lung Cancer Treatment
2025 · Zi‐Han Ye, Wei‐Bang Yu, et al. · Advanced Science · 8
Xerophenone H, a naturally-derived proteasome inhibitor, triggers apoptosis and paraptosis in lung cancer
2025 · Wen-Yu Lyu, Jun Cao, et al. · Phytomedicine · 6
Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells
2023 · Xinyu HE, Jiarui FU, et al. · Chinese Journal of Natural Medicines · 5
Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and in vitro Studies
2022 · Hong Zhao, Jin-Jian Lu, et al. · Current Cancer Drug Targets · 4
The PD-1/PD-L1 axis in cancer: from immune evasion mechanisms to next-generation therapeutics
2026 · Le-Le Zhang, Yi Wang, et al. · Molecular Cancer
Works count: 22
Citation count: 1,000
H-index: 17
I10-index: 17
Year
Topic
Type